n(g),n(g')-dimethyl-l-arginine has been researched along with ADPKD in 3 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| "ADPKD patients with higher serum uric acid levels had a higher asymmetric dimethylarginine (ADMA) level (1." | 5.17 | Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. ( Axelsson, J; Eroglu, E; Kalay, N; Kocyigit, I; Orscelik, O; Oymak, O; Sipahioglu, MH; Tokgoz, B; Unal, A; Yilmaz, MI, 2013) |
| "In experimental models of polycystic kidney disease impaired bioavailability of nitric oxide (NO) and elevated mRNA expression of oxidative stress markers at the kidney level was noted." | 1.39 | Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. ( Georgianos, PI; Grekas, DM; Kapoulas, S; Makedou, A; Makedou, K; Raptis, V; Sarafidis, PA; Sioulis, A, 2013) |
| "Patients with autosomal dominant polycystic kidney disease (ADPKD) with normal renal function have endothelial dysfunction and decreased nitric oxide synthase activity in subcutaneous resistance vessels." | 1.35 | Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. ( Borresen, ML; Connors, SG; Luo, Z; Strandgaard, S; Wang, D; Wilcox, CS; Yan, Q, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kocyigit, I | 1 |
| Yilmaz, MI | 1 |
| Orscelik, O | 1 |
| Sipahioglu, MH | 1 |
| Unal, A | 1 |
| Eroglu, E | 1 |
| Kalay, N | 1 |
| Tokgoz, B | 1 |
| Axelsson, J | 1 |
| Oymak, O | 1 |
| Raptis, V | 1 |
| Georgianos, PI | 1 |
| Sarafidis, PA | 1 |
| Sioulis, A | 1 |
| Makedou, K | 1 |
| Makedou, A | 1 |
| Grekas, DM | 1 |
| Kapoulas, S | 1 |
| Wang, D | 1 |
| Strandgaard, S | 1 |
| Borresen, ML | 1 |
| Luo, Z | 1 |
| Connors, SG | 1 |
| Yan, Q | 1 |
| Wilcox, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endothelial Dysfunction in Patients With Polycystic Kidney Disease[NCT01589705] | 150 participants (Actual) | Observational | 2012-01-31 | Terminated (stopped due to Patients recruitment and analysis were terminated) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for n(g),n(g')-dimethyl-l-arginine and ADPKD
| Article | Year |
|---|---|
Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Arginine; C-Reactive Protein; Cross-Sectional Studies; Endothelium, Vascular; Glomerular Filt | 2013 |
2 other studies available for n(g),n(g')-dimethyl-l-arginine and ADPKD
| Article | Year |
|---|---|
Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Aged; Arginine; Dinoprost; Disease Progression; Female; Glomerular Filtration Rat | 2013 |
Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.
Topics: Adult; Arginine; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Enzyme Inhibitors; Femal | 2008 |